SynthesisAsian journal of andrology
Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review.
Synthesis in Asian journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis.Current medicinal chemistry · 2024Pooled it
- Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis.Scientific reports · 2018Pooled it
- Atorvastatin as a pleiotropic anticancer agent: mechanisms, evidence, and therapeutic repurposing potential.Frontiers in immunology · 2026Review
- The association between statin use, genetic variation, and prostate cancer risk.Prostate cancer and prostatic diseases · 2025Article
- Simvastatin inhibits PD-L1 via ILF3 to induce ferroptosis in gastric cancer cells.Cell death & disease · 2025Article
- Association of genetically instrumented HMGCR inhibition with the therapeutic role of prostate cancer: a Mendelian randomization study and supportingFrontiers in pharmacology · 2025Article
- Effects of the Prior Use of Statins on Head and Neck Cancer Risk: A Hospital-Based Case-Control Study.Pharmaceuticals (Basel, Switzerland) · 2022Article
- The Association of Prediagnostic Statin Use with Aggressive Prostate Cancer from the Multiethnic Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Association of Statin Use with the Risk of Incident Prostate Cancer: A Meta-Analysis and Systematic Review.Journal of oncology · 2022Article
- The Effect of Statins in Cancer Risk Reduction in Patients on Dialysis: A Population-Based Case-Control Study.Journal of clinical medicine · 2021Article
- The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer.Cancer causes & control : CCC · 2021Article
- Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality.Scientific reports · 2021Article
- Independent and Joint Effects of Testosterone Replacement Therapy and Statins use on the Risk of Prostate Cancer Among White, Black, and Hispanic Men.Cancer prevention research (Philadelphia, Pa.) · 2021Article
- Pharmacoepidemiological Evaluation in Prostate Cancer-Common Pitfalls and How to Avoid Them.Cancers · 2021Review
- Associations between Statin/Omega3 Usage and MRI-Based Radiomics Signatures in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- Sustainable functional urethral reconstruction: Maximizing early continence recovery in robotic-assisted radical prostatectomy.Asian journal of urology · 2021Article
- Uptake of high-density lipoprotein by scavenger receptor class B type 1 is associated with prostate cancer proliferation and tumor progression in mice.The Journal of biological chemistry · 2020Article
- Cancer Progress and Priorities: Prostate Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.The Prostate · 2020Article
- Association of statin use with risk of Gleason score-specific prostate cancer: A hospital-based cohort study.Cancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to investigate the effect of statins type or even when grouping statins by hydrophilic or hydrophobic nature on prostate cancer risk. A literature search was performed without language restrictions using the databases of PubMed (1984.1-2015.3), MEDLINE (1984.1-2015.3), and EMBASE (1990.1-2015.3). Two independent reviewers appraised eligible studies and extracted data. Weighted averages were reported as relative risk (RR) with 95% confidence intervals (CI). Statistic heterogeneity scores were assessed with the standard Cochran's Q-test and I2 statistic. Publication bias was detected using the Begg's and Egger's tests. All statistical analyses were conducted by STATA version 10. Finally, fourteen studies were included in the meta-analysis. Both hydrophilic and hydrophobic statins showed no association with incidence of prostate cancer (RR = 1.00, 95% CI: 0.82-1.17; RR = 0.90, 95% CI: 0.73-1.08, respectively). Meanwhile, the risk of prostate cancer was not reduced in simvastatin (RR = 0.89, 95% CI: 0.72-1.05), pravastatin (RR = 1.02, 95% CI: 0.94-1.11), atorvastatin (RR = 0.89, 95% CI: 0.76-1.02), fluvastatin (RR = 0.99, 95% CI: 0.97-1.01), or lovastatin users (RR = 0.94, 95% CI: 0.79-1.08). The funnel plot showed that there was no publication bias. The results showed that statins had a neutral effect on prostate cancer risk; hydrophilic and hydrophobic statins as well as any subtype of statins did not affect the risk of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.